The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and Gilead/Kite’s Yescarta for relapsed or refractory aggressive NHL herald a new era in cancer immunotherapy. In this series of special reports, we present a comprehensive analysis of currently available and upcoming CAR T-cell therapies. This report will examine the CAR T-cell treatment landscape: the technology behind it, the hurdles to and drivers of adoption, pricing strategies, physicians’ views, and the outlook for this paradigm-shifting treatment approach.
- How is CAR T-cell therapy being adopted into medical practice? What kind of referral patterns are in place for potentially eligible patients? What is the typical patient journey for someone receiving CAR T-cell therapy?
- What are developers doing to ensure that the myriad manufacturing issues are optimized and scalable to meet patient demand? What kind of marketing and educational programs are available to ensure that patients, physicians, and institutions are well informed about side effects, post-treatment monitoring, etc.?
- What additional services are available for patients—e.g., specialist nurse/technician services, patient care after receiving CAR T-cell therapy, services for caregivers?
- What pricing strategies are being implemented to cover the high cost of this therapy? Are risk-sharing and/or cost-sharing agreements in place? Are upfront payments required? What is the additional cost of patient care at specialist centers during the CAR T-cell manufacturing process and following administration?
Special Topics Report Series is a three-wave series based on KOL interviews conducted at 1, 6, and 12 months postcommercial launch and on secondary data collected from a variety of sources. We capture physicians’ awareness, perception, and use of the launched product and anticipated future trends.